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Abstract Dysferlin is a transmembrane protein that is
highly expressed in muscle. Dysferlin mutations cause
limb-girdle dystrophy type 2B, Miyoshi myopathy and
distal anterior compartment myopathy. Dysferlin has
also been described in neural tissue. We studied dysfer-
lin distribution in the brains of patients with Alzheimer
disease (AD) and controls. Twelve brains, staged using
the Clinical Dementia Rating were examined: 9 AD
cases (mean age: 85.9 years and mean disease duration:
8.9 years), and 3 age-matched controls (mean age:
87.5 years). Dysferlin is a cytoplasmic protein in the
pyramidal neurons of normal and AD brains. In addi-
tion, there were dysferlin-positive dystrophic neurites
within A plaques in the AD brain, distinct from tau-
positive neurites. Western blots of total brain protein
(RIPA) and sequential extraction buVers (high salt,
high salt/Triton X-100, SDS and formic acid) of
increasing protein extraction strength were performed
to examine solubility state. In RIPA fractions, dysferlin
was seen as 230–272 kDa bands in normal and AD
brains. In serial extractions, there was a shift of dysfer-
lin from soluble phase in high salt/Triton X-100 to the
more insoluble SDS fraction in AD. Dysferlin is a new
protein described in the AD brain that accumulates in
association with neuritic plaques. In muscle, dysferlin
plays a role in the repair of muscle membrane damage.
The accumulation of dysferlin in the AD brain may be
related to the inability of neurons to repair damage due
to A deposits accumulating in the AD brain.
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Introduction
Aggregation of neuronal proteins is a common mecha-
nistic theme in neurodegenerative diseases [13].
Whether due to point mutations or post-translational
modiWcation, normally soluble proteins are altered and
form insoluble Wbrillar aggregates [18]. Alzheimer’s
disease (AD), the most common form of dementia, is
characterized pathologically by abundant diVuse and
neuritic plaques throughout most cortical regions.
Amyloid -protein (A) is a 39–43 amino acid peptide
cleaved from a larger precursor protein (amyloid
precursor protein or APP) that deposits extracellularly
as senile plaques either as loose, nonWbrillar diVuse
plaques, or as a more compacted, Wbrillar form, with
dystrophic neurites coursing through the plaque [25].
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Other aggregated proteins found in the AD brain
include the microtubule-associated protein tau [11] as
neuroWbrillary tangles and the presynaptic protein -
synuclein [13] in the form of Lewy bodies.
The alteration, deposition and aggregation of amy-
loid proteins may be an ill-fated response to the disease
process or themselves lead to a cascade of cellular
responses ultimately resulting in neuronal dysfunction
and death.
Nonbrain protein aggregates have been described in
muscle disease. For example, amyloid-like deposits
have been described in inclusion body myositis [2].
Other protein aggregates found in muscle disease
include desmin-related myopathies, actinopathies and
myosinopathies [30]. Aggregates containing these pro-
teins have not been described in brain disease. Another
muscle protein associated with myopathy is dysferlin.
Dysferlin is a plasma membrane and cytoplasmic vesi-
cle-associated protein implicated in three adult-onset
muscle diseases (limb-girdle dystrophy, type 2B, Miyo-
shi myopathy and distal anterior compartment myo-
pathy)[4, 9, 22, 24]. Although described in peripheral
nerve [30] and demonstrated by Western blot in human
and mouse brain [21], there is little known about the
function of dysferlin in the brain or its role in neuro-
degenerative disease. We describe the pattern of dysferlin
expression in the normal and AD brain and examine
dysferlin accumulation in association with amyloid
deposition in the brains of AD patients.
Materials and methods
Case materials
Case materials were derived from research participants
in a longitudinal study of healthy aging and dementia
who were studied postmortem. The diagnostic criteria
are consistent with probable AD reported by the
National Institute of Neurological and Communicative
Disorders and Stroke and Alzheimer’s Disease and
Related Disorders Association [26] and conWrmed by
autopsy to meet high probability of AD according to
National Institute of Aging-Reagan criteria [28]. The
clinical dementia rating (CDR) was used to determine
the presence or absence of dementia and stage its
severity [27]. The global CDR is derived by a synthesis
of individual ratings in six cognitive and functional
categories where CDR = 0 indicates no dementia and
CDR = 0.5, 1, 2, or 3 corresponds to very mild, mild,
moderate, or severe dementia [27]. The CDR is closely
correlated with the presence of dementia pathology at
autopsy [14]. The Washington University Human Stud-
ies Committee approved all procedures.
Twelve brains were examined. Three cases were
rated as nondemented (CDR 0) with a mean age of
87.5 years. Nine AD brains were examined; three each
of mild (CDR 1), moderate (CDR 2) and severe (CDR
3). The mean age of the demented cases was 85.9 years
with mean disease duration of 8.9 years (Table 1). Con-
trol cases were all Braak stage I or II [6]. Sampling
during postmortem exam was done from 29 diVerent
cortical, subcortical and brainstem regions. ParaYn-
embedded sample for this study were taken from mid-
frontal, cingulate and entorhinal regions; three sections
were stained for each antibody with appropriate con-
trols [15]. Biochemistry was performed on midfrontal
gyrus adjacent to the section taken for immunohisto-
chemistry for each case.
Immunohistochemistry
Immunohistochemistry was done as previously
described [14, 15]. BrieXy, serial 6 m sections of para-
Table 1 Sample characteristics and Wndings at postmortem examination
Case Age 
(years)
Sex CDR Disease 
duration 
(years)
Brain 
wt (g) 
Braak scores CERAD 
criteria
NIA–Reagan 
criteria
NeuroWbrillary Amyloid
1 92 F 0 – 1,120 II A – –
2 85 F 0 – 1,100 I A – –
3 92 F 0 – 1,210 I A – –
4 85 F 1 8 1,200 IV C DeWnite High
5 99 M 1 2 1,230 V B DeWnite High
69 5 M 1 1 4 1 , 3 6 0 V C D e Wnite High
78 1 M 2 1 6 7 9 0V I C D e Wnite High
89 1 M 2 1 1 1 , 5 8 0 V B D e Wnite High
9 90 M 2 7 1,170 IV B DeWnite High
10 86 M 3 10 1,310 VI C DeWnite High
11 79 F 3 8 770 VI C DeWnite High
12 88 M 3 11 1,130 VI C DeWnite HighActa Neuropathol (2006) 112:665–671 667
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formaldehyde-Wxed, paraYn-embedded tissue were
prepared and incubated overnight at 4°C with anti-
bodies against dysferlin (Novacastra Laboratories), tau
(17026, gift from J. Trojanowski), and amyloid -
protein (6E10, Signet). Sections were developed by
avidin–biotin complex method (Vector Laboratories)
for immunohistochemistry with DAB (brown), Vector
Red (pink) and Vector SG (blue) as chromogens.
Alexa-Red and Green (Jackson Laboratories) antibod-
ies were used for immunoXuorescence. Sections were
examined with a Nikon E800 Research microscope,
and images were digitized and viewed with AnalySIS
analytic software (Soft Imaging Systems, GmbH).
Western blots
Western blotting and biochemical fractionation were
performed as described previously [16]. BrieXy, two
sections of gray matter (0.3 g) from the midfrontal
cortex of AD and normal age-matched control brains
were dissected from underlying white matter. After
dissection, gray matter was divided into two samples
(Fig. 1). One sample was homogenized in RIPA
(150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate,
1% NP-40, 50 mM Tris, pH 8, 20 mM, NaF, 2 mM
EGTA, 0.5% levamisole, 1 mM NaVO4) to estimate
total dysferlin. The other sample was homogenized and
subjected to sequential extraction buVers of increasing
protein extraction strength. For each buVer, pellets
were washed twice and supernatants pooled. Samples
were Wrst homogenized in 2 ml/gram of tissue of high-salt
(HS) buVer (50 mmol/l Tris, pH 7.4, 750 mmol/l NaCl,
10 mmol/l NaF, 5 mmol/l ethylenediaminetetraacetic
acid with protease inhibitors) and centrifuged at
100,000g for 30 min. The pellets were re-extracted and
the supernatants were pooled. The pellets were
sequentially extracted twice with 2 ml/gram of HS
buVer/1% Triton X-100 (HS/T) and once with 1 ml/
gram sodium dodecyl sulfate (SDS) sample buVer (1%
SDS, 10% sucrose, 10 mmol/l Tris, pH 6.8, 1 mmol/l
ethylenediaminetetraacetic acid, 40 mmol/l dithiothrei-
tol). The pellets were extracted with 0.67 ml/g 70%
formic acid (FA) and disrupted with two sequential 2-s
sonication bursts. FA was evaporated in a vacuum cen-
trifuge (Eppendorf). SDS sample buVer (0.67 ml/g) was
added to the dried pellets, followed by vigorous vortex,
and the pH was adjusted with NaOH. SDS sample
buVer was added to the HS and HS/Triton fraction and
all of the samples were boiled for 5 min. The FA sam-
ples were centrifuged at 13,000g for 5 min to remove
insoluble debris. Five microliters of each fraction was
loaded in separate lanes for SDS-polyacrylamide gel
electrophoresis followed by Western blot analysis with
antibodies again dysferlin. The immune complexes
were visualized with the use of the ECL Plus kit
(Amersham) according to the manufacturer’s protocol.
The autoradiographs obtained were scanned and the
band intensity quantiWed utilizing TotalLab software
(Nonlinear Dynamics, Newcastle on Tyne, UK). Statis-
tical analyses were performed by analysis of variance
using SPSS statistical software.
Results
Localization of dysferlin in normal (CDR 0) brain
Microscopic evaluation of the dysferlin staining in the
normal (CDR 0) brain localized expression to the cyto-
plasm of large pyramidal neurons of layers III, V and
VI in the neocortex (Fig. 2a), layer II neurons of the
entorhinal cortex, CA 1–3 neurons in the hippocampus
and large projection neurons in the amygdala (not
shown). Dysferlin was not localized to astrocytes,
endothelial cells or microglia (arrowheads in Fig. 2b).
Little to no dysferlin neuritic staining was seen in con-
trol cases (Braak stage I or II).
Dysferlin in the AD brain
Dysferlin neuritic accumulation is found throughout
the AD brain and in double-label studies it is localized
in A neuritic plaques in the neocortex (Fig. 3a).
Double-labeled studies demonstrate co-localization of
Fig. 1 Schematic representation of sequential protein extraction
buVers. Samples are divided into equal portions. The Wrst sample
is homogenized in RIPA buVer and blotted to estimate total dys-
ferlin levels. The other sample is homogenized in sequential
extraction buVers of increasing protein extraction strength. The
Wrst extraction is in high-salt (HS) buVer. The supernatants are
saved and the pellet is extracted with HS buVer/1% Triton X-100
(HS/T) buVer. After saving the supernatants, the resultant pellet
is homogenized in sodium dodecyl sulfate (SDS) sample buVer.
Resulting pellets are Wnally extracted with 70% formic acid (FA).
Supernatants are blotted to estimate diVering levels of dysferlin
solubility with the HS fraction representing the most soluble
phase and the FA fraction representing the most insoluble phase668 Acta Neuropathol (2006) 112:665–671
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dysferlin (brown in Fig. 3b) and A (pink in Fig. 3b) in
the hippocampus.
Dysferlin neuritic pathology occurs in conjunction 
with tau neuritic pathology
In Fig. 4, we demonstrate that neurites in plaques may
comprise tau, dysferlin or both. Triple-labeled studies
of midfrontal (Fig. 4a), cingulate (Fig. 4b) and entor-
hinal (Fig. 4c) cortex illustrate the relationship of tau
(pink, arrowheads) and dysferlin (brown, arrows)
within an A plaque (blue). Double-labeled immuno-
Xuorescent studies (Fig. 4d–f) demonstrate that tau
(green in 4d) and dysferlin (red in Fig. 4e) have both
distinct and overlapping (yellow in Fig. 4f) epitopes in
neuritic plaques. Dysferlin does not appear to co-local-
ize with the more abundant tau dystrophic neurites.
Biochemistry
Western blot analysis following RIPA extraction dem-
onstrated the presence of dysferlin as 230–272 kDa
bands in all brains examined (Fig. 5a); however, there
was a decrease in the total dysferlin content in CDR 3
(severe AD) brains compared to CDR 0 (nonde-
mented). There is a progressive decrease in total dys-
ferlin with progressive disease (r = 0.998,  P =0 . 0 0 1 ) .
Western blot analysis following serial extraction of
proteins demonstrated a change in the solubility state
of dysferlin across the spectrum of dementia (Fig. 5b).
No dysferlin could be demonstrated in the HS fraction.
In contrast to the control CDR 0 brains, however,
there was a signiWcant reduction of dysferlin in the HS/
T fraction in the demented cases (CDR 1 and 2) and
was undetectable at the CDR 3 level of severity
Fig. 2 Localization of dysferlin in brains of nondemented sub-
jects. a, b Demonstrates the localization of dysferlin immunoreac-
tivity in the brain. There is a neuronal expression of dysferlin
localized in cytoplasm of large pyramidal (layers III, V, VI) neu-
rons in the frontal cortex at low power (a). Little to no neuritic
staining was detected. Dysferlin expression is conWned to neurons
(arrow, DAB brown in b) and is not seen in glial cells stained with
GFAP (small arrowheads, Vector Red pink in b). MagniWcation
of (a) is 100£ and the scale bar in (a)=5 0m. MagniWcation of
(b) is 400£ and the scale bar in (b)=2 0m
Fig. 3 Localization of dysferlin with amyloid pathology in the
AD brain. a, b Demonstrates the location of the dysferlin accu-
mulation in the AD brain with double-labeled studies. a DiVuse
dysferlin accumulation (DAB, brown) and A (DAB-nickel,
black) in the frontal cortex. Using VectorRed (pink, Vector Lab-
oratories) as the chromogen for A and DAB (brown, Vector
Laboratories) as the chromogen for dysferlin, the pathologic
deposition is localized as neuritic pathology in A neuritic
plaques in the neocortex hippocampus (b). MagniWcation of (a) is
100£ and the scale bar in (a)=2 0m. MagniWcation of (b) is
200£ and the scale bar in (b)=2 0mActa Neuropathol (2006) 112:665–671 669
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(F = 2,991,  P < 0.001). In the SDS-soluble fraction
from the demented cases, there was an accumulation of
230–272 kDa bands with dementia progression, that is
a more insoluble form of dysferlin was found in severe
CDR 3 brains compared to milder stages of dementia
(CDR 1) or in nondemented individuals (F =3 , 1 8 3 ,
P < 0.001). Dysferlin did not aggregate or accumulate
in the FA-soluble fractions of the control or AD
brains.
Discussion
Dysferlin is a new protein described in the AD brain
associated with neuritic plaques. Dysferlin is widely
expressed in the brain and is found in intracytoplasmic
compartments in pyramidal neurons in normal brains.
Dysferlin begins to accumulate in dystrophic neurites
in the AD brain at mild stages of dementia (CDR 1).
Dysferlin is found at all stages of disease with greater
accumulation in more advanced disease (CDR 3).
SigniWcantly, our Western blot analysis demon-
strated dysferlin in RIPA-extracted fraction in all
cases; however, in the serial extracted fractions an
alteration in the solubility state of dysferlin was found
in demented cases (CDR > 1) compared with non-
demented cases. This coincides with the Wnding of
neuritic pathology by immunohistochemistry. The HS/T
fraction represents the transmembrane cytoskeletal
fraction of normal dysferlin and decreases with
advanced stages of dementia. This may represent the loss
of membrane integrity and alteration in cytoskeleton
structure. In contrast, the SDS-soluble fraction represents
more insoluble forms of the protein suggesting aggre-
gation of dysferlin may be related to disease progres-
sion. This alteration of solubility and accumulation is
seen in other neurodegenerative diseases (e.g. Parkin-
son’s disease, multiple system atrophy, dementia with
Lewy bodies) [15, 31].
Dysferlin is a member of ferlin family, homologous
to fer1 protein in C. elegans [5]. It is highly expressed in
muscle but little is known about the role of the protein
in the brain. Several members of the ferlin family have
been mapped. Dysferlin is found on chromosome 2p13
[1] and deWciency is associated with three clinical phe-
notypes: Limb-Girdle muscular dystrophy, type 2B,
Miyoshi myopathy and distal anterior compartment
myopathy [20, 22, 24]. Another member of the ferlin
family, Otoferlin is mapped to chromosome 2p23 and
is associated with autosomal recessive nonsyndromic
deafness [31]. Two other members of the ferlin family
have been described: Myoferlin (10q24) [7] and FerlL4
(20q11) [12]. Myoferlin is a type II transmembrane
protein upregulated in Duchenne muscular dystrophy
and may have a role in muscle regeneration and repair
[10]. The function of Fer1L4 is unknown.
Dysferlin is thought to play a role in muscle mem-
brane maintenance and repair [3, 4, 9, 12, 19]. In C. ele-
gans, the Fer1 protein plays a role in vesicle traYcking
and membrane fusion and can bind to phospholipids in a
calcium-dependent manner [22]. In dysferlin null-mice,
muscle cells are defective in repairing membrane disrup-
tions leading to degeneration [4, 21, 23]. If dysferlin has
a similar membrane repair function in neurons, then it is
Fig. 4 Localization of dysferlin with tau pathology in the AD
brain.  a–f Demonstrates the location of the dysferlin and tau
accumulation in the AD brain with triple-labeled immunohisto-
chemistry studies (a–c) and double-labeled immunoXuorescence
studies (d–f). a Midfrontal, b cingulate and c entorhinal demon-
strate tau (Vector Red, pink,  arrowheads), dysferlin (DAB,
brown, arrows) and A (Vector SG, blue). Note the distinction
between tau-positive and dysferlin-positive structures. Double-
labeled immunoXuorescence studies demonstrated neurites within
amyloid plaques. Neurites may comprise tau (green, d), dysferlin
(red, e) or overlapping epitopes (yellow in merged image of f).
MagniWcation of (a–f) is 600£ and the scale bar in (d)=2 0m670 Acta Neuropathol (2006) 112:665–671
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possible that the deposition of dysferlin in AD may be
related to the inability of neurons to repair damage due
to accumulating A pathology throughout the progres-
sion of AD. The Wndings reported suggest that there
may be common mechanisms of membrane repair in
degenerative diseases of muscle (e.g. dystrophinopathies
and sarcoglycanopathies) and brain (e.g. AD).
The aggregation of normally soluble proteins in
Wbrillar lesions is the neuropathologic hallmark of
many neurodegenerative diseases. Whether the aggre-
gates or their precursors are the actual toxic species is
still under debate [8]; however, it is likely that the con-
version of proteins from a soluble to insoluble state
impairs the long-term viability of neurons. In addition,
because dysferlin appears to accumulate in conjunction
with A deposition and disease progression it may be
able to serve as a marker of disease progression. Con-
tinued eVorts aimed at understanding abnormalities in
the misfolding of protein leading to neurodegenerative
disease such as A and tau, or proteins associated with
aggregation such as dysferlin will provide insights into
disease mechanisms underlying neurological disorders
characterized by abundant Wlamentous lesions.
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